



To: Kaiser Permanente Network Physicians **Date:** February 20, 2020
Subject: Notice to MDs: KPNW Network Provider **From:** Sean Jones, MD
Notification of Part D Negative Formulary Emily Thomas, PharmD
Change 2020 Formulary Services

As a part of our due diligence to inform all concerned of Medicare Part D Formulary Changes, the following notification is requested by CMS to be sent to all Providers.

Medicare Part D Benefit Coverage – Product removal

During the year, with Medicare approval, we may make changes to our Drug List.

- We may add new drugs, remove drugs, and add or remove restrictions on coverage for drugs. We are also allowed to change drugs from one cost-sharing tier to another.
- Unless noted otherwise, you will have at least 30-day notice before any changes take effect unless a serious safety issue is involved (for example, a drug is taken off the market by the Food and Drug Administration (FDA) or the drug manufacturer removes it).

Product Removal: Concerta extended release tablets (18 mg, 27 mg, 36 mg, 54 mg)

Effective April 1, 2020, the brand-name drug: Concerta extended release tablets (18 mg, 27 mg, 36 mg, 54 mg) will be removed from the KP Medicare Part D Drug List as generic alternative is now available.

Affected members who were prescribed this drug prior to April 1, 2020 will be grand fathered and continue to receive the product.

Reason for change	Drug Name/Description	Date and Type of Change:	Alternate Drug (Note: Over-the-counter (OTC) drugs are not covered under the Medicare Part D benefit)
Generic Available	CONCERTA TBCR 18MG, 27MG, 36MG, 54MG	April 1, 2020 Brand drug to be replaced with generic	METHYLPHENIDATE HCL ER TBCR 18MG, 27MG, 36MG, 54MG